Intermediate-term outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipients

American Journal of Surgery
Kristian L BrownScott A Gruber

Abstract

Prior studies have yielded conflicting results concerning the impact of HCV on renal transplant outcomes. We examined outcomes in comparable groups of predominantly African American hepatitis C virus (HCV)-positive (n = 34) and HCV-negative (n = 111) kidney transplant patients receiving contemporary immunosuppression. There was no difference in patient survival or acute rejection, but new-onset diabetes (NODM) was increased and graft survival decreased in the HCV-positive group, with increased graft loss secondary to noncompliance and Type I MPGN. The incidence of NODM among patients undergoing early corticosteroid withdrawal was 11% in both groups, while among those on prednisone, it was 47% in HCV-positive versus 25% in HCV-negative recipients. Deceased-donor HCV-positive renal allograft recipients have equivalent patient but decreased graft survival. Noncompliance and Type I MPGN play a role in producing this negative effect on graft outcome. Steroids may be required for HCV to exert its diabetogenicity in kidney transplant patients.

References

Dec 24, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P MathurinM O Bitker
Jul 31, 2001·Transplantation·H U Meier-KriescheB Kaplan
Jul 9, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D S BattyK C Abbott
Oct 22, 2003·Journal of the American Society of Nephrology : JASN·Kevin C AbbottThomas G Peters
Oct 31, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·John R Lake
Jan 9, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ihab M MahmoudMohamed A Sobh
May 15, 2004·Clinical Transplantation·Hsin-Hung LinSheng-Hsieh Chu
Jul 6, 2004·Clinical Transplantation·Enver AkalinJonathan S Bromberg
Sep 17, 2004·Transplantation·Annette BruchfeldCarl-Gustaf Elinder
May 13, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Fabrizio FabriziGareth Dulai
Sep 16, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Fabrizio FabriziGareth Dulai
Mar 22, 2006·Transplantation Proceedings·G Manga SahinH Ergin
Jul 28, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A HaririanS A Gruber
Aug 16, 2006·Transplantation Proceedings·S PedrosoA Cabrita
Jan 2, 2007·Transplantation·Tariq ShahSuphamai Bunnapradist

❮ Previous
Next ❯

Citations

Mar 12, 2016·Transplantation Reviews·Johann PratschkeFriedrich Thaiss
Feb 12, 2009·Transplant International : Official Journal of the European Society for Organ Transplantation·Tao ChenHaoming Tian
Oct 15, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Yvon LebranchuPeter Friend
May 29, 2016·Transplantation Proceedings·R CarpioE Que
Feb 5, 2009·Clinical Transplantation·Kristian L BrownScott A Gruber
Jul 2, 2009·The International Journal of Artificial Organs·Fabrizio FabriziPaul Martin
Mar 17, 2010·American Journal of Surgery·Kristian L BrownScott A Gruber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.